...development into a new drug, X. They also have to account for the royalty payments that Pharmagen will owe Company XYZ in the future. Pharmagen pharmaceutical company is working on developing a new drug, X. They have been self-funding the research and development costs. They entered into a Funding Agreement with Company XYZ, a private equity investor, who has agreed to provide Pharmagen with up to $500 million of the total cost needed to develop drug X over the estimated 3 year project time frame. Pharmagen is not obligated to successfully complete the drug and there are no performance obligations related to its development. The money received from XYZ is nonrefundable. However, the money provided by XYZ can only be used towards drug X. If Pharmagen successfully completed the drug and it is approved for public sale, XYZ will receive future royalty payments from both drug X and an existing drug that is already available for public sale. Pharmagen also retains the rights to drug X. Pharmagen should report their cash from XYZ Corporation as deferred income based on ASC 470-10-25-1 (Sales of Future Revenues). It states that when “an entity receives cash from an investor and agrees to pay the investor,” in this case a royalty of future sales, “it is assumed that immediate income recognition is not appropriate due to the facts and circumstances.” Therefore, I believe that Pharmagen should be reporting their royalties, when they are received, as deferred and not immediate income. ...
Words: 658 - Pages: 3
...CONFIDENTIAL LICENCE_AGREEMENT ORIGINAL 15DEC2011 MODIFICATION JAN 24 2013 AMENDED AND RESTATED LICENCE_AGREEMENT This license agreement (hereinafter called “Agreement”), made and entered into as of January 24, 2013(the “Effective Date”), is by and between: ABCCanada inc., and LICENCE CO, (“LICENCE CO”), hereinafter sometimes individually referred to as “Party” and collectively as “Parties.” WHEREAS LICENCE CO is a limited partnership which has been created to manage the intellectual property rights of the ■ (hereafter “UNIVERSITY”) and other third parties; and WHEREAS, ■ developed an innovation related to ■ (the “Invention”), which has been partially disclosed in the patent application …, the (“Patents”). WHEREAS, ■ has assigned its intellectual property rights in the Technology to LICENCE CO through an assignment of intellectual property rights signed on June 16, 2005. WHEREAS, ABC CO has entered into a term sheet with LICENCE CO establishing the basic terms of an eventual licensing agreement between the Parties on August 5, 2011 (the “Term Sheet”). WHEREAS, LICENCE CO and ABC CO has entered into a license agreement on December 15, 2011, which allows the Technology of LICENCE CO to be used by ABC CO for commercial purposes. WHEREAS the Parties agree that such licence agreement shall be amended in order to rectify errors and omissions found in the Agreement. NOW THEREFORE IN CONSIDERATION of the above recitals and the mutual benefits to be derived hereafter, the Parties agree...
Words: 6221 - Pages: 25
...Voltamp Electrical Corporation Letter of Transmittal To, The Vice President, Voltamp Electrical Corporation. Subject- To access the situation and come up with a proposition in order to exploit the commercial possibilities of the new magnetic material, TGW. The report consists of the analysis of both the aspects of both the departments of Voltamp- Magnetic Material Section and Audio Product Section respectively and to find out which department is best suited for the production of the new magnetic material- TGW. The sales for both the departments are being taken into consideration. Yours Sincerely, John Carter (Manager, Audio Products Section) Situational Analysis The Advanced Development Laboratory, who was responsible for the development and research, discovered the new magnetic material which was later on offered to the Audio Product Section. The new material-TGW had the capacity to have a higher stability and the cost was cheaper as compared to the existing product and it also had various new features which could easily replace the current product. The feature of this new product was that it had a greater commercial application than those originally envisioned. TGW also had the capacity to gain reputation along with the market leadership. The product also had the ability to improve its marketing competitive position. It could benefit the current existing product as well as the new range of products with the help of the new material product...
Words: 978 - Pages: 4
...1. Towards the end of his medical training in the early 1980s, Gokhan Hotamisligil was working on a unique tumor case on a patient and found they were comprised primarily of fat cells. The fatty tumors were due to a rare condition, Proteus Syndrome. Working in the field of metabolic regulation Hotamisligil began to explore the underlying pathways for insulin resistance. In his dissertation he discovered that the fat tissue of obese animals and humans were capable of producing inflammatory mediators. His research helped shape the current view of fat tissue as a “discrete, active organ in its own right, continuously exchanging messages with the rest of the body by way of the bloodstream.” By early 2002 Hotamisligil and his laboratory made several groundbreaking discoveries linking inflammation, to obesity, diabetes, and related cardiovascular problems. Hotamisligil’s publications have appeared numerous times in all of the major scientific journals, including Nature and Science. In 2004, Hotamisligil was able to demonstrate that excess fat, by itself can cause stress signals and medical problems. In the field of metabolic health and disease it is clear that Hotamisligil has played an extremely important role in its development, with his numerous contributions and many publications in the field. Since starting his career back in the 80s he helped to shape the modern view of metabolic health and took important steps towards understanding underlying causes of Type 2 diabetes and metabolic...
Words: 1018 - Pages: 5
...International Legal and Ethical Issues Simulation Analysis Businesses must ensure legal protection from other foreign country companies from adverse actions. There is high risk in international business transactions and CadMex need to protect against them. Steps to protect the business legally is crucial when selecting the choice-of-law, and selecting clause in the simulation. Establishing terms in a contract is important factor in a business partnership between foreign countries to protect interests for each party. After completing the first section of the simulation identifying the choose-of-law in the United States regarding specific contracts is Contract of International Sale of Goods (CISG) for domestic business transactions that cover marketing ProPez. CISG laws cover the use of technology in this case with Gentura; however, does not cover licensing or patents. International Arbitration non-binding contract provides variety of dispute resolution organizations to resolve contract disputes may take a year instead of awaiting court availability in this case, it is less expensive, and recognize contract internationally. This option safeguards CadMex’s interest with certain contingencies under contract law applicable in this case. After Candore gained World Trade Organization (WTO) the best choice remains CISG fits terms in the contract cover marketing ProPez and technical training, but does not cover patents and licensing. In March 2007 an unidentifiable...
Words: 641 - Pages: 3
...income • The place of performance of the services • FCT v Efstathakis – Greek national worked for the Greek Press in Aust. → Source of income was Aust - performed relevant work • FCT v French – Australian engineer employed by Aust to work in NZ. → Service was performed in NZ, source of income was NZ • Other factors, such as place of contracting or place of payment may determine source • FCT v Mitchum – American actor entered agreement with Swiss co. Worked on film in Aust. Salary was paid in US. → NO Australian Source - No law stating that source of salary is where work is performed • Evans v FCT – Academic employed by University of Adelaide worked in Switzerland. Received study leave grant was paid in Australian bank account. → Australian source, basis of place of payment Business income • Permanent establishment • Place where business carried on • FCT v United Aircraft Corp – Taxpayer was US resident company, provided info (know how) to reps of an Australia co. who use info to manufacture aircrafts in Aust. Australia paid US. Deemed as royalty payments → No source in Australia – info was supplied in US, payments were not attributable to operations of US or to Australian property Interest income • The source of interest income is the place where the credit is provided: o The place of contracting OR o The place where the funds are advanced • Commer of IR v Philips Gloeilampenfabrieken • Business loans – Where business carried on Dividends • s44(1) ITAA36:...
Words: 508 - Pages: 3
...From the case material we can see that the value of licensing arrangement consists of three parts: Initial investment, Milestone Payment and Royalty Fee. In Phase 1, Merck has to pay LAB 5 million initial investment no matter whether Davanrik will get approved by FDA in future. In Phase 2, Merck has to pay LAB 2.5 million Milestone payment if Davanrik successfully complete Phase 1 with a probability of 60%. In Phase 3, the amount of milestone payment Merck has to pay depends on the result of Phase 2. If Davanrik successfully complete phase 2 and was effective only for depression with the probability of 10%, then Merck has to pay 20 million to LAB. If Davanrik successfully complete phase 2 and was effective only for weight loss with the probability of 15%, then Merck has to pay 10 million to LAB. If Davanrik successfully complete phase 2 and was effective for both depression and weight loss with the probability of 5%, then Merck has to pay 40 million to LAB. When finishing all three phases and getting approval by FDA, Merck has to pay Royalty fee to LAB based on the sales with 5% fee rate. After finish all three phases, there is a chance of 85% that Merck can launch Davanrik if the Phase 3 showed that it was only effective for depression and the commercialized present value is 1.2 billion. The chance decreased to 75% if Merck can only be effective for weight loss with 345 million commercialized present value. If Davanrik is effective for both, the chance of successfully launch...
Words: 406 - Pages: 2
...Merck & Company: Evaluating a Drug Licensing Opportunity Case Summary Merck & Company (Merck) a large pharmaceutical company was approached by LAB Pharmaceuticals in 2000 for the purchase option to license and provide funding for a newly developed drug compound called Davanrik. If Merck, the licensee purchased the compound it would be responsible for the design, administration, and funding of the clinical testing of the compound, as well as take care of its manufacturing and marketing. LAB the licensor would receive an initial payment followed by additional payments as Davanrik completes each clinical testing phase. Davanrik was initially developed to treat depression but during the pre-clinical development process the drug not only blocked antidepressant receptors but also blocked the receptor that causes hunger allowing the compound to angle it to treat depression and obesity. At the time Mercks most popular drugs such as Pepid, Prinivil, Vasotec, Mevacor’s patents were due to be expired in 2002. Since generic substitutions would essentially replace these compounds, Merck could stand to lose almost 50% of its sales revenue equating to a $5.7 billion loss if it did not come up with a new drug to bring to the market. Under the current conditions of potential loss Rich Kender, the Vice President of Financial Evaluation & Analysis at Merck was considering acquisition of the new compound Davanrik from LAB. Kender worked with a tem to decide whether the company...
Words: 592 - Pages: 3
...There are four different types of royalties in the music recording and publishing industry that are paid to the composer of a work, each derived from a separate and distinct copyright. These are Mechanical royalties, public performance royalties, synchronization fees and print music royalties (Strand, Kouchoukas and Rattner, p.6). Mechanical royalties are fees that are paid to the copyright owner of a song for the right to reproduce the song on a recording. Public performance royalties are paid by music users for each performance or broadcast of performance based on the exclusive right to perform publicly copyrighted works (Strand, Kouchoukas and Rattner, p.6). Synrchonization fees are required any time the performance of a song is accompanied by visual images. Finally, there is print music royalties where a song writer receives royalties from a print license any time sheet music of his song or a folio or collection of his songs is sold (Strand, Kouchoukas and Rattner, p.7). In addition to royalties there are copyright laws where one can obtain a copyright for the work he/she has created and produced. A copyright is described as a bundle of rights, having evolved to embrace virtually every form of reproducing and using creative works in both the physical and the online worlds, ranging from photocopying sheet music to downloading music from the internet and from performing a musical work to webcasting a performance (Faulder). Rights of copyright are exclusive to the owner of copyright...
Words: 328 - Pages: 2
...audit is needed to make sure everyone is getting what they are entitled to whether it is the artist, songwriter, or the producer. I will discuss the roles of a royalty auditor and the process they go through during their audits. I will also point out royalty frauds that can occur within the music industry. But first, I will explain exactly what a royalty is and how it works. How Royalties Work A main concern in the music industry is royalties. It is the main source of income for anyone who has something to do with a particular song. A royalty is a payment made for the use of property, such as a patent, copyrighted work, franchise, or a natural resource (Investor Words). It can be a percentage of profit from sales and will be settled by an agreement (usually in writing) between the parties (Obringer). Songwriters and publishers have different royalties than the artist who performs it or records vocals on the song. The artist gets royalties from the sale of their recordings such as CDs. One misconception in the music industry is that the artist gets royalties from public performances such as when their song gets played on the radio or television, but in fact the songwriters and publishers get those royalties from those instances (Obringer). There are four general categories of royalties. Mechanical licenses and royalties refer to the permissions granted to record the songwriters’ song and publicly distribute it. Performance...
Words: 1538 - Pages: 7
...and royalty payments. The other issue is to identify the authoritative literature applicable to this funding arrangement and to discuss the appropriate accounting for the Agreement in accordance with that guidance. 2. The facts: a. Pharma enters into an agreement with Company XYZ, a PEI. b. Pharma to receive up to $500 million from the PEI for R&D for the development of a new drug. c. The PEI is to participate financially in the development of X. d. The funding is to be solely used for the development of X. e. The amounts received is non-refundable and Pharma is not obligated to successfully complete the development of X. f. Pharma will receive incremental funding from the PEI as long as Pharma is showing progress towards the development of X. g. The total estimated costs are $1 billion and the development will take 3 years. h. Pharma retains all the intellectual property rights to X. i. There will be no joint marketing agreements nor will there be collaboration agreements. j. The PEI is entitled to receive royalties associated with the revenues of X and future royalties associated with an existing commercialized drug for a defined period. 3. ASC-730-20 is applicable here. This is because Pharmgen is entering into an agreement with PEI (investors) on a contractural basis to provide services for the R&D results (FASB 68). Pharmgen obtains the exclusive rights to the results in return for royalty payments to the PEI. The royalties represent a contingent payment. Thought...
Words: 658 - Pages: 3
...Trueblood case 09-2: Pharmagen Pharmagen case describes a $500 million Research and Development (“R&D”) funding agreement between pharmaceutical company (“Pharma”) and third-party private investor (“PEI”). The issue is to decide on how to account for funding of the R&D and royalty payments, and identify authoritative literature applicable to the agreement. Case states the following facts about agreement: • Pharma will receive up to $500 million from PEI for R&D cost for new drug X • A non-refundable funding to be used solely for drug X development costs • PEI will provide incremental funding as long as Pharma is demonstrating progress, however Pharma is not obligated to successfully complete development, “best effort”arrangement • Pharma estimated completion of project will take 3 years (from agreement date), and will cost estimated $1 billion • Pharma retains all intellectual property rights to drug X • PEI is entitled to receive future royalties on drug X revenues • PEI is entitled to receive future royalties associated with an existing commercialized drug Facts presented in the case call for Accounting Standards Codification (ASC) section 730-20 to be applicable. This accounting standard provides clarification and guidance to entities that entered into R&D arrangements, and advises on proper recognition. To define how transactions in Pharma and PEI agreement should be recorded, we should take a close look...
Words: 1356 - Pages: 6
...Tolemite: Obtain a payment of all past and future liabilities at the highest royalty possible, or the highest payment. * BARD: They would benefit from two situations: 1.CKC wining the trial, as they would not have to pay royalties anymore, which could decrease CKC’s cost competitive advantage if BARD decides to lower the price of the product. Thus they can become more competitive and may increase their market share this way. 2. CKC having to pay a royalty of 4% or more. The same logic as above applies. What should Mr. Purcell do? If you think he should propose a settlement, what amount do you recommend, and how should it be communicated? I believe Mr. Purcell should propose a settlement with Tolemite. The process started on 2005, and only in 2009 they are going to trial, which means 4 years of related costs, including time and monetary costs. Moreover, if they do go to trial, the process may continue, as appeals can be made if they win the case. This will mean more years with this problem in mind, and costly lawyers and advisors. By the time the trial is over, the patent will be close to expiring (2017), thus decreasing the importance of the trial itself. Regardless of the calculations made, paying 7.5% royalty (in the model calculated this would be an acceptable value) will affect the sales of the product as well, because it will mean that they will loose the competitive advantage CKC had over BARD in addition to the cost of the royalty. Moreover, BARD...
Words: 799 - Pages: 4
...public officials are not allowed to receive gratuity from agencies that have interest in regulations that those officials may be even remotely connected to. The jury involved convicted Diamond, and the District court subsequently sentenced them to pay a fine of $400,000. Afterwards the Court of Appeals reversed the stated conviction and remanded a new trial. Discussion of the Facts: Who did what to whom? What relief is being sought? Example - Sony manufacturers Betamax video tape recorders for use in recording a TV Broadcast. Tapes can be viewed, erased, and use to record again. Universal City and Disney Studios claim that Sony is facilitating the theft and reproduction of movies, and denying them their rightful copyright royalty...
Words: 656 - Pages: 3
...February 3, 2015 Mr. Kender, Merck and Company has been presented with a very interesting opportunity from LAB Pharmaceuticals. After having analyzed the current opportunity that Merck and Company is being presented with we have come up with the following recommendations on how best for you and your company to proceed with this proposal to purchase LAB Pharmaceuticals new drug, Davanrik. We feel that purchasing the rights to Davanrik is a great opportunity for Merck and Company to expand its product portfolio, customer base and future revenues. That being said, there are risks associated with taking on the costly and lengthy FDA approval processes that goes along with it. After having performed our analysis, based in part by the use of the attached decision tree, we have concluded that the maximum that Merck and Company should be willing to offer LAB Pharmaceuticals for the rights to Davanrik is $13.68 million. Also, in order to be more confident in the financial outlook for this plan we also elected to perform a sensitivity analysis. The analysis was run based on a worse case scenario and assumed an increase of launch costs from $100 million to $225 million for the weight loss compound in the third phase of the launch. If Merck and Company was to experience these added costs we would expect to see value of $10.76 million. Within the attached report you will find our detailed analysis, which has led us to the above conclusion. The report also outlines the...
Words: 2390 - Pages: 10